Scilex Holding Company announces exclusive product distribution agreement with CH Trading Group LLC to commercialise ZTlido across certain designated territories including Middle East and North Africa
Scilex Holding Company announced the signing of a Product Distribution Agreement (“Agreement”) for certain designated territories with CH Trading Group LLC (“CH Trading”), an international import, export and trading company focused on the Middle East and North Africa (MENA) Region and other markets, to distribute Scilex’s lead non-opioid commercial pain management product, ZTlido. Scilex is a nearly 100% (or over 99.9%) majority-owned subsidiary of Sorrento Therapeutics, Inc.
“We are delighted to work with a non-opioid pain management leader like Scilex for distribution of ZTlido into these markets,” said Elsayed Zayan, CEO of the CH Group family of companies, which include CH Trading. “Our mission is to promote healthy, ethical and productive lifestyle, including bringing innovative products to people throughout the OIC countries and the GCC and MENA Regions. Aligning with Scilex’s global ambitions means that together we can help more patients, partners, and public health systems collectively benefit.”
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins